Research programme: metabolic disorders kinase inhibitors - Arrien PharmaceuticalsAlternative Names: ARN-2089
Latest Information Update: 17 Sep 2012
At a glance
- Originator Arrien Pharmaceuticals
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Obesity; Type 2 diabetes mellitus
Most Recent Events
- 17 Sep 2012 Early research is ongoing in USA